| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Claudio Ponticelli | |
| Giovanni Banfi | |||
| P2860 | cites work | Hemolytic uremic syndrome. Recurrence after renal transplantation. Groupe Coopératif de l'Ile-de-France (GCIF). | Q33332155 |
| Thrombotic microangiopathy early after kidney transplantation: hemolytic uremic syndrome or vascular rejection? | Q33332843 | ||
| Autosomal dominant hemolytic uremic syndrome: variable phenotypes and transplant results | Q33332934 | ||
| Familial hemolytic uremic syndrome associated with complement factor H deficiency | Q33336276 | ||
| Complement factor H: physiology and pathophysiology | Q33338067 | ||
| De novo hemolytic uremic syndrome after kidney transplantation in patients treated with cyclosporine-sirolimus combination | Q33341564 | ||
| Post-transplant hemolytic-uremic syndrome | Q33343588 | ||
| TTP/HUS occurring in a simultaneous pancreas/kidney transplant recipient after clopidogrel treatment: evidence of a nonimmunological etiology | Q33344550 | ||
| Shiga toxin-associated hemolytic uremic syndrome: absence of recurrence after renal transplantation | Q33344663 | ||
| De novo thrombotic microangiopathy in renal transplant recipients: a comparison of hemolytic uremic syndrome with localized renal thrombotic microangiopathy | Q33346269 | ||
| Thrombotic micro-angiopathy with sirolimus-based immunosuppression: potentiation of calcineurin-inhibitor-induced endothelial damage? | Q33346767 | ||
| Successful (?) therapy of hemolytic-uremic syndrome with factor H abnormality | Q33348763 | ||
| Thrombotic microangiopathy and cytomegalovirus in liver transplant recipients: a case-based review | Q33349933 | ||
| The risk of recurrence of hemolytic uremic syndrome after renal transplantation in children | Q33352815 | ||
| Renal transplantation in patients with hemolytic uremic syndrome: high rate of recurrence and increased incidence of acute rejections | Q33356853 | ||
| Von Willebrand factor--cleaving protease activity in thrombotic microangiopathy after living donor liver transplantation: a case report | Q33357681 | ||
| Attempted treatment of factor H deficiency by liver transplantation | Q33359768 | ||
| Atypical relapse of hemolytic uremic syndrome after transplantation | Q33362060 | ||
| Anti-Factor H autoantibodies associated with atypical hemolytic uremic syndrome | Q33364092 | ||
| Hemolytic uremic syndrome: a fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation | Q33365746 | ||
| Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome | Q33366172 | ||
| Follow-up of kidney graft recipients with cyclosporine-associated hemolytic-uremic syndrome and thrombotic microangiopathy | Q33366519 | ||
| Hemolytic uremic syndrome: an example of insufficient complement regulation on self-tissue | Q33369747 | ||
| Calcineurin inhibitor-free immunosuppression in renal allograft recipients with thrombotic microangiopathy/hemolytic uremic syndrome. | Q33369997 | ||
| Antiviral drugs. | Q33598295 | ||
| Cyclosporine nephrotoxicity | Q35299740 | ||
| The role of vascular endothelial growth factor (VEGF) in renal pathophysiology | Q35776377 | ||
| Immunosuppressive drugs for kidney transplantation. | Q35992328 | ||
| The role of postischemic reperfusion injury and other nonantigen-dependent inflammatory pathways in transplantation. | Q36064737 | ||
| Sirolimus may promote thrombotic microangiopathy | Q44326132 | ||
| Outcome of Plasma Exchange Therapy in Thrombotic Microangiopathy After Renal Transplantation | Q44596912 | ||
| Increased risk of thrombotic microangiopathy in patients receiving a cyclosporin-sirolimus combination | Q44899011 | ||
| Thrombotic microangiopathy and cytomegalovirus disease in patients infected with human immunodeficiency virus | Q45763694 | ||
| Inhibitors of ADAMTS13: a potential factor in the cause of thrombotic microangiopathy in a renal allograft recipient. | Q45970480 | ||
| Sirolimus-induced thrombotic microangiopathy is associated with decreased expression of vascular endothelial growth factor in kidneys | Q46702750 | ||
| Thrombotic microangiopathy in marginal kidneys after sirolimus use. | Q46822614 | ||
| Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome | Q57703229 | ||
| P433 | issue | 10 | |
| P921 | main subject | kidney transplantation | Q740909 |
| P304 | page(s) | 789-794 | |
| P577 | publication date | 2006-10-01 | |
| P1433 | published in | Transplant International | Q15762140 |
| P1476 | title | Thrombotic microangiopathy after kidney transplantation | |
| P478 | volume | 19 |
| Q33395560 | A case of tacrolimus-associated thrombotic microangiopathy after ABO-blood-type-incompatible renal transplantation |
| Q37193631 | A primer on recurrent and de novo glomerulonephritis in renal allografts |
| Q33409802 | Acute graft dysfunction after living-related renal transplant |
| Q33378684 | Acute kidney injury in solid organ transplant recipients |
| Q33414342 | An analysis of transplant glomerulopathy and thrombotic microangiopathy in kidney transplant biopsies |
| Q51333222 | Antibody mediated rejection associated with complement factor h-related protein 3/1 deficiency successfully treated with eculizumab. |
| Q33423267 | Atypical hemolytic uremic syndrome diagnosed four years after ABO-incompatible kidney transplantation |
| Q33411363 | Blood disorders after kidney transplantation |
| Q36641955 | Characteristics and Outcomes of Renal Transplant Recipients with Hemolytic Uremic Syndrome in the United States |
| Q42086661 | Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea |
| Q92627201 | Consensus regarding diagnosis and management of atypical hemolytic uremic syndrome |
| Q33421909 | Cytomegalovirus-induced thrombotic microangiopathy after renal transplant successfully treated with eculizumab: case report and review of the literature |
| Q55128066 | De Novo Atypical Haemolytic Uremic Syndrome after Kidney Transplantation. |
| Q27005877 | De novo glomerular diseases after renal transplantation |
| Q41019245 | De novo mTOR inhibitor-based immunosuppression in ABO-incompatible kidney transplantation |
| Q33403602 | De novo thrombotic microangiopathy after kidney transplantation: clinical features, treatment, and long-term patient and graft survival |
| Q33439133 | De novo thrombotic microangiopathy following simultaneous pancreas and kidney transplantation managed with eculizumab |
| Q40426421 | Didactic lessons from the serum lactate dehydrogenase posttransplant: a clinical vignette |
| Q33908301 | Differing tales of two patients after receiving a kidney transplant from a donor with disseminated intravascular coagulation |
| Q53180638 | Eculizumab for the treatment of atypical hemolytic uremic syndrome recurrence after kidney transplantation associated with complement factor H mutations: a case report with a 5-year follow-up. |
| Q33395870 | Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation--a case report |
| Q33404327 | Eculizumab treatment of acute antibody-mediated rejection in renal transplantation: case reports |
| Q54355912 | Effect of antihypertensive treatments on insulin signalling in lympho-monocytes of essential hypertensive patients: a pilot study. |
| Q33417767 | Everolimus, cyclosporine, and thrombotic microangiopathy: clinical role and preventive tools in renal transplantation |
| Q47912606 | Impact of treatment and outcomes for patients with posttransplant drug-associated thrombotic microangiopathy |
| Q34133898 | Intracellular molecular effects of insulin resistance in patients with metabolic syndrome |
| Q90641306 | Metastatic lung adenocarcinoma- associated thrombotic microangiopathy in a renal transplant recipient |
| Q57151742 | Pathology of Calcineurin and Mammalian Target of Rapamycin Inhibitors in Kidney Transplantation |
| Q33394870 | Plasmapheresis therapy in renal transplant patients: five-year experience. |
| Q24601710 | Recurrent atypical hemolytic uremic syndrome associated with factor I mutation in a living related renal transplant recipient |
| Q33375364 | Retinal injury as an early manifestation of posttransplant thrombotic microangiopathy: recovery with plasma exchanges and conversion to sirolimus--case report and review of the literature |
| Q38669190 | Safety of mTOR inhibitors in adult solid organ transplantation. |
| Q36554196 | Tacrolimus associated localized thrombotic microangiopathy developing in early stage after renal transplantation |
| Q33426548 | The inferior impact of antibody-mediated rejection on the clinical outcome of kidney allografts that develop de novo thrombotic microangiopathy. |
| Q33391882 | The role of endothelial cell injury in thrombotic microangiopathy |
| Q33376858 | The thrombotic microangiopathies. |
| Q50085453 | Thrombotic Microangiopathy and the Kidney |
| Q33398129 | Thrombotic microangiopathy after living-donor liver transplantation |
| Q33424525 | Thrombotic microangiopathy caused by severe graft dysfunction after living donor liver transplantation: report of a case |
| Q33388329 | Thrombotic microangiopathy following intestinal transplantation: a single center experience |
| Q33389749 | Thrombotic thrombocytopenic purpura associated with everolimus use in a renal transplant patient |
Search more.